|
|
|
|
| LEADER |
03378nam a22003255i 4500 |
| 001 |
978-3-7091-9278-8 |
| 005 |
20191023221935.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121227s1993 au | s |||| 0|eng d |
| 020 |
|
|
|a 9783709192788
|
| 024 |
7 |
|
|a 10.1007/978-3-7091-9278-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Measles and Poliomyelitis
|b Vaccines, Immunization, and Control /
|c edited by Edouard Kurstak.
|
| 250 |
|
|
|a 1st ed. 1993.
|
| 260 |
# |
# |
|a Vienna :
|b Springer Vienna :
|b Imprint: Springer,
|c 1993.
|
| 300 |
|
|
|a XI, 411 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Editor’s introduction Measles and poliomyelitis: vaccines, immunization, and control -- I. Measles Global Control -- 1. Challenges for the global control of measles in the 1990’s -- 2. The experience with measles in the United States -- 3. Mass vaccination programme aimed at eradication of measles in Sweden -- 4. Identification of high risk groups for measles immunization -- 5. Is measles eradicable? -- 6. Safety of measles vaccines -- 7. Measles vaccines—one versus two doses: why and when -- 8. Cost-benefit analysis of a second dose measles inoculation of children -- 9. High-titer measles virus vaccines: protection evaluation -- 10. Recent approaches in the development of measles vaccines -- 11. Molecular biological basis of measles virus strain differences -- 12. Measles virus antigenic variations and the role of individual antigens in immunization -- 13. Cell-mediated immune response to measles virus -- II. Towards Poliomyelitis Eradication -- 14. Lessons from poliovirus control: strategies for eradication -- 15. Eradication of poliomyelitis: countdown or slowdown -- 16. The potential for poliovirus eradication -- 17. Poliovirus immunization situation in China -- 18. Epidemiologic and laboratory classification systems for paralytic poliomyelitis cases -- 19. Monitoring of the environment as a means of poliovirus surveillance -- 20. Criteria for the certification of poliomyelitis eradication -- 21. Poliovirus vaccine formulations -- 22. Inactivated and live attenuated poliovirus vaccines: mucosal immunity -- 23. Immunogenicity of poliovirus vaccines with special reference to the choice between oral and inactivated vaccines in developing countries -- 24. Optimal schedule for the administration of oral poliovirus vaccine -- 25. Poliovirus combined immunization with inactivated and live attenuated vaccines -- 26. Antigenicity and immunogenicity of inactivated poliovirus vaccine in combined vaccine trials -- 27. Studies aiming at improvement of inactivated poliovirus vaccine preparations -- 28. Development of candidates for new types 2 and 3 oral poliovirus recombinant vaccines -- 29. Intratypic differentiation of polioviruses -- 30. Natural evolution of oral vaccine poliovirus strains -- 31. Stability of attenuated poliovirus strain genotypes in the human intestinal tract.
|
| 650 |
|
0 |
|a Vaccines.
|
| 650 |
|
0 |
|a Internal medicine.
|
| 650 |
|
0 |
|a Virology.
|
| 650 |
1 |
4 |
|a Vaccine.
|
| 650 |
2 |
4 |
|a Internal Medicine.
|
| 650 |
2 |
4 |
|a Virology.
|
| 700 |
1 |
|
|a Kurstak, Edouard.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7091-9278-8
|